A series of monochlorotriazine reactive antibacterial agents were synthesised by using 2,4,4’ - trichloro -2’ - hydroxydiphenyl ether as a starting material. The spectrum analyses (UV and MS) and elementary analy-se...A series of monochlorotriazine reactive antibacterial agents were synthesised by using 2,4,4’ - trichloro -2’ - hydroxydiphenyl ether as a starting material. The spectrum analyses (UV and MS) and elementary analy-ses were also carried out. These antibacterial agents can be used as the bacteria - resistance finishing agents of the cellulose fabrics. The treated fabrics possess excellent antibacterial activity and durable wash fastness. For ex-ample , the percentages of bacterial reduction of the fab-ric finished with reactive antibacterial agent 2RSDP are 98.5%, 98. 86% and 96.67% for Staphylococcus au-reus, Escherichia coli and Pseudomonas aeruginose re-spectively. After more than 100 times of washing at 60°C, the antibacterial activity still retains at a level of about 90% of the original. The relationships between the molecular structures of the reactive antibacterial finish-ing agents and their antibacterial activities are discussed.展开更多
Cancer cells utilize cytosolic glycolysis for their energy production even in the presence of adequate levels of oxygen (Warbug effect) due to mitochondrial defects. Dichloroacetic acid (DCA) shifts cytosolic glucose ...Cancer cells utilize cytosolic glycolysis for their energy production even in the presence of adequate levels of oxygen (Warbug effect) due to mitochondrial defects. Dichloroacetic acid (DCA) shifts cytosolic glucose metabolism to aerobic oxidation by inhibiting mitochondrial pyruvate dehydrogenase kinase (PDK) and increasing pyruvate uptake. Therefore, DCA has potential in reversing the glycolytic metabolism defect in cancerous cells. DCA is also known to induce apoptosis in a number of cancer cell lines, the mechanism of which is not well understood. In this study, an attempt has been made to investigate the effects of DCA on aggressive human breast cancer (MCF-7) cells as compared with less aggressive mouse osteoblastic (MC3T3) cells. Cell cytotoxicity was determined by MTT, crystal violet and Trypan blue exclusion assays. Western blot was used to detect any changes in the expression of apoptotic markers. Flow cytometry was used to measure apoptotic and necrotic effects of DCA. Mitochondrial integrity was determined by change in mitochondrial membrane potential (Δψm), whereas oxidative damage was determined by production of reactive oxygen species (ROS). DCA caused a concentration-dependent cytotoxicity both in MCF-7 and MC3T3 cell lines. MCF-7 cells were most affected. Flow cytometry results showed a significantly higher apoptosis in MCF-7 even at lower concentrations of DCA. However, higher concentrations of DCA were necrotic. Western blotting showed an increased expression of Mn-SOD-1 upon DCA treatment. Further, DCA decreased Δψm and increased ROS production. The effects of DCA were more pronounced on MCF-7 cells as compared to MC3T3 cells. Our results suggest that DCA-induced cytotoxicity in cancerous cells is mediated via changes in Δψm and production of ROS.展开更多
Poor interfacial adhesion between biobased thermoplastics and natural fibers is recognized as a major drawback for biocomposites.To be applicable for the large-scale production,a simple method to handle is of importan...Poor interfacial adhesion between biobased thermoplastics and natural fibers is recognized as a major drawback for biocomposites.To be applicable for the large-scale production,a simple method to handle is of importance.This work presented poly(lactic acid)(PLA)reinforced with short-fiber and three reactive agents including anhydride and epoxide groups were selected as compatibilizers.Biocomposites were prepared by one-step meltmixing methods.The influence of reactive agents on mechanical,dynamic mechanical properties and morphology of PLA biocomposites were investigated.Tensile strength and storage modulus of PLA biocomposites incorporated with epoxide-based reactive agent was increased 13.9%and 37.4%compared to non-compatibilized PLA biocomposite,which was higher than adding anhydride-based reactive agent.SEM micrographs and Molau test exhibited an improvement of interfacial fiber-matrix adhesion in the PLA biocomposites incorporated with epoxide-based reactive agent.FTIR revealed the chemical reaction between the fiber and PLA with the presence of epoxide-based reactive agents.展开更多
AIM To assess the incidence of hepatitis B virus(HBV) reactivation in patients receiving direct-acting antiviral agent(DAA)-based therapy or interferon(IFN)-based therapy for hepatitis C and the effectiveness of preem...AIM To assess the incidence of hepatitis B virus(HBV) reactivation in patients receiving direct-acting antiviral agent(DAA)-based therapy or interferon(IFN)-based therapy for hepatitis C and the effectiveness of preemptive antiHBV therapy for preventing HBV reactivation.METHODS The Pub Med, MEDLINE and EMBASE databases were searched, and 39 studies that reported HBV reactivation in HBV/hepatitis C virus coinfected patients receiving DAAbased therapy or IFN-based therapy were included. The primary outcome was the rate of HBV reactivation. The secondary outcomes included HBV reactivation-related hepatitis and the effectiveness of preemptive anti-HBV treatment with nucleos(t)ide analogues. The pooled effects were assessed using a random effects model. RESULTS The rate of HBV reactivation was 21.1% in hepatitis Bsurface antigen(HBs Ag)-positive patients receiving DAAbased therapy and 11.9% in those receiving IFN-based therapy. The incidence of hepatitis was lower in HBs Agpositive patients with undetectable HBV DNA compared to patients with detectable HBV DNA receiving DAA therapy(RR = 0.20, 95%CI: 0.06-0.64, P = 0.007). The pooled HBV reactivation rate in patients with previous HBV infection was 0.6% for those receiving DAA-based therapy and 0 for those receiving IFN-based therapy, and none of the patients experienced a hepatitis flare related to HBV reactivation. Preemptive anti-HBV treatment significantly reduced the potential risk of HBV reactivation in HBs Agpositive patients undergoing DAA-based therapy(RR = 0.31, 95%CI: 0.1-0.96, P = 0.042).CONCLUSION The rate of HBV reactivation and hepatitis flare occurrence is higher in HBs Ag-positive patients receiving DAA-based therapy than in those receiving IFN-based therapy, but these events occur less frequently in patients with previous HBV infection. Preemptive anti-HBV treatment is effective in preventing HBV reactivation.展开更多
基金Ph.D.Research Foundation of the Ministry of National Education
文摘A series of monochlorotriazine reactive antibacterial agents were synthesised by using 2,4,4’ - trichloro -2’ - hydroxydiphenyl ether as a starting material. The spectrum analyses (UV and MS) and elementary analy-ses were also carried out. These antibacterial agents can be used as the bacteria - resistance finishing agents of the cellulose fabrics. The treated fabrics possess excellent antibacterial activity and durable wash fastness. For ex-ample , the percentages of bacterial reduction of the fab-ric finished with reactive antibacterial agent 2RSDP are 98.5%, 98. 86% and 96.67% for Staphylococcus au-reus, Escherichia coli and Pseudomonas aeruginose re-spectively. After more than 100 times of washing at 60°C, the antibacterial activity still retains at a level of about 90% of the original. The relationships between the molecular structures of the reactive antibacterial finish-ing agents and their antibacterial activities are discussed.
文摘Cancer cells utilize cytosolic glycolysis for their energy production even in the presence of adequate levels of oxygen (Warbug effect) due to mitochondrial defects. Dichloroacetic acid (DCA) shifts cytosolic glucose metabolism to aerobic oxidation by inhibiting mitochondrial pyruvate dehydrogenase kinase (PDK) and increasing pyruvate uptake. Therefore, DCA has potential in reversing the glycolytic metabolism defect in cancerous cells. DCA is also known to induce apoptosis in a number of cancer cell lines, the mechanism of which is not well understood. In this study, an attempt has been made to investigate the effects of DCA on aggressive human breast cancer (MCF-7) cells as compared with less aggressive mouse osteoblastic (MC3T3) cells. Cell cytotoxicity was determined by MTT, crystal violet and Trypan blue exclusion assays. Western blot was used to detect any changes in the expression of apoptotic markers. Flow cytometry was used to measure apoptotic and necrotic effects of DCA. Mitochondrial integrity was determined by change in mitochondrial membrane potential (Δψm), whereas oxidative damage was determined by production of reactive oxygen species (ROS). DCA caused a concentration-dependent cytotoxicity both in MCF-7 and MC3T3 cell lines. MCF-7 cells were most affected. Flow cytometry results showed a significantly higher apoptosis in MCF-7 even at lower concentrations of DCA. However, higher concentrations of DCA were necrotic. Western blotting showed an increased expression of Mn-SOD-1 upon DCA treatment. Further, DCA decreased Δψm and increased ROS production. The effects of DCA were more pronounced on MCF-7 cells as compared to MC3T3 cells. Our results suggest that DCA-induced cytotoxicity in cancerous cells is mediated via changes in Δψm and production of ROS.
文摘Poor interfacial adhesion between biobased thermoplastics and natural fibers is recognized as a major drawback for biocomposites.To be applicable for the large-scale production,a simple method to handle is of importance.This work presented poly(lactic acid)(PLA)reinforced with short-fiber and three reactive agents including anhydride and epoxide groups were selected as compatibilizers.Biocomposites were prepared by one-step meltmixing methods.The influence of reactive agents on mechanical,dynamic mechanical properties and morphology of PLA biocomposites were investigated.Tensile strength and storage modulus of PLA biocomposites incorporated with epoxide-based reactive agent was increased 13.9%and 37.4%compared to non-compatibilized PLA biocomposite,which was higher than adding anhydride-based reactive agent.SEM micrographs and Molau test exhibited an improvement of interfacial fiber-matrix adhesion in the PLA biocomposites incorporated with epoxide-based reactive agent.FTIR revealed the chemical reaction between the fiber and PLA with the presence of epoxide-based reactive agents.
文摘AIM To assess the incidence of hepatitis B virus(HBV) reactivation in patients receiving direct-acting antiviral agent(DAA)-based therapy or interferon(IFN)-based therapy for hepatitis C and the effectiveness of preemptive antiHBV therapy for preventing HBV reactivation.METHODS The Pub Med, MEDLINE and EMBASE databases were searched, and 39 studies that reported HBV reactivation in HBV/hepatitis C virus coinfected patients receiving DAAbased therapy or IFN-based therapy were included. The primary outcome was the rate of HBV reactivation. The secondary outcomes included HBV reactivation-related hepatitis and the effectiveness of preemptive anti-HBV treatment with nucleos(t)ide analogues. The pooled effects were assessed using a random effects model. RESULTS The rate of HBV reactivation was 21.1% in hepatitis Bsurface antigen(HBs Ag)-positive patients receiving DAAbased therapy and 11.9% in those receiving IFN-based therapy. The incidence of hepatitis was lower in HBs Agpositive patients with undetectable HBV DNA compared to patients with detectable HBV DNA receiving DAA therapy(RR = 0.20, 95%CI: 0.06-0.64, P = 0.007). The pooled HBV reactivation rate in patients with previous HBV infection was 0.6% for those receiving DAA-based therapy and 0 for those receiving IFN-based therapy, and none of the patients experienced a hepatitis flare related to HBV reactivation. Preemptive anti-HBV treatment significantly reduced the potential risk of HBV reactivation in HBs Agpositive patients undergoing DAA-based therapy(RR = 0.31, 95%CI: 0.1-0.96, P = 0.042).CONCLUSION The rate of HBV reactivation and hepatitis flare occurrence is higher in HBs Ag-positive patients receiving DAA-based therapy than in those receiving IFN-based therapy, but these events occur less frequently in patients with previous HBV infection. Preemptive anti-HBV treatment is effective in preventing HBV reactivation.
